Search Results
Keyword：neuroendocrine tumors
FDA Approves Lantheus' Bravnetsa for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) has formally approved Lantheus Holdings' radioligand therapy drug Bravnetsa (lutetium Lu 177 dotatate injection) for the treatment of somatostatin receptor-positive adult gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approved indication covers neuroendocrine tumors originating from the foregut, midgut, and hindgut. Following FDA review, Bravnetsa has been determined to be bioequivalent and therapeutically equivalent to Novartis'...
2026-09-27
Curium's Lutetium-177 Injection Approved by FDA for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Radiopharmaceutical company Curium recently announced that its developed lutetium-177 (Lu-177) dotatate injection (trade name: Bexlutry) has received formal approval from the U.S. Food and Drug Administration (FDA). The drug is indicated for the treatment of somatostatin receptor-positive adult gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The specific indication scope includes various neuroendocrine tumors occurring in the adult foregut, midgut, and hindgut. Bexlutry is an advanced radioligand therapy whose mechanism of action lies in its ability to specifically bind to somatostatin receptors highly expressed on the surface of such tumors. Through this precise binding, the drug can deliver...
2026-09-16